Rouzier Clinical Intelligence
Rouzier Clinical IntelligencePhysician Intelligence

For licensed clinicians

Evidence with Confidence

Research, analysis, and Dr. Rouzier's expertise — all in one place.

Intelligence network connecting research, evidence analysis, Rouzier commentary, and clinical application
Popular

40M+

Research studies indexed

Published clinical literature

12M+

Full-text articles

PMID, DOI, full abstracts

30+

Years of teaching

Dr. Rouzier seminars & webinars

10+

Clinicians learning

And growing every month

Why clinicians choose Rouzier Clinical Intelligence

Evidence First — every answer is backed by real studies and verifiable sources.
Critical Analysis — go beyond the abstract with strengths, limitations, and conflicting evidence.
Expert Guidance — Dr. Rouzier's teaching and commentary at your fingertips.
Time Back — get to the truth faster with intelligence built for clinicians.

Trusted by 1,000+ licensed clinicians

Ask the Evidence

Top evidence for your question

Product demonstration
Fertility and Sterility2022

Testosterone therapy and cardiovascular risk: advances and controversies

Contemporary synthesis does not support categorical cardiovascular harm from appropriately indicated testosterone therapy.

Evidence: HighRelevance: High
Sample trial card2023

TRAVERSE: cardiovascular safety of testosterone in hypogonadal men

Large randomized cardiovascular-safety evidence for testosterone in a high-risk hypogonadal population.

Evidence: HighRelevance: High
JAMA (observational sample)2013

Association of testosterone therapy with mortality, MI, and stroke in men with low testosterone

An influential observational signal that raised CV concern and later required careful methodological critique.

Evidence: ModerateRelevance: High

Evidence answer

For appropriately selected hypogonadal men, current higher-quality evidence does not support a blanket increase in major cardiovascular events from testosterone replacement. Risk still depends on indication, formulation, monitoring, and baseline cardiovascular status.

View full answer

Evidence at a glance

HIGH

Evidence strength

Higher-quality contemporary trials and syntheses outweigh older observational signals.

Fertility and Sterility 2022

Sample trial card 2023

JAMA (observational sample) 2013

Citations

  • [1] Fertility and Sterility · 2022

    Testosterone therapy and cardiovascular risk: advances and controversies

  • [2] Sample trial card · 2023

    TRAVERSE: cardiovascular safety of testosterone in hypogonadal men

  • [3] JAMA (observational sample) · 2013

    Association of testosterone therapy with mortality, MI, and stroke in men with low testosterone

Published evidence vs Rouzier

Literature and teaching, side by side

Rouzier intelligenceVerified demo commentaryWorldLink archive

Sleep, nutrition, and resistance training are foundational — hormones work best when lifestyle physiology is addressed.

Lifestyle Medicine in Hormone Optimization

Video hosted on WorldLink Medical. Transcript and chapters in this app are illustrative for the demo.

Webinar intelligence

0:00

Lifestyle Medicine in Hormone Optimization

Dr. Neal Rouzier

Chapters

You cannot out-prescribe a broken lifestyle. Sleep deprivation alone can suppress testosterone, worsen insulin resistance, and amplify menopausal symptoms. Before we escalate doses, we ask about sleep. Nutrition, fasting patterns, gut health, and resistance training change hormone signaling. These are not alternative medicine — they are first-line physiology. I integrate lifestyle medicine into every hormone plan: realistic exercise, protein adequacy, alcohol moderation, stress boundaries, and environmental exposures where relevant. The best hormone clinicians are also lifestyle clinicians. Patients feel the difference.

Published evidence

Literature synthesis

Current literature synthesis does not support categorical cardiovascular harm from appropriately indicated testosterone therapy in hypogonadal men.

Rouzier intelligence

Dr. Rouzier's perspective

Sleep, nutrition, and resistance training are foundational — hormones work best when lifestyle physiology is addressed.

Where they align

Both treat testosterone as context-dependent rather than universally dangerous or universally safe.

Where they differ

Practice thresholds for hematocrit and unstable cardiovascular disease remain clinical judgment.

New evidence since commentary

Newer randomized cardiovascular-safety data continue to update early-2010s observational controversy.

This week in evidence

View research

International journal of impotence research

Testosterone replacement therapy and cardiovascular disease.

Compare studies

Study A vs Study B

Sample comparison
Randomized controlled trialRetrospective cohort
DesignRandomized controlled trialRetrospective cohort
Participants5,2468,709
Follow-upMean ~22 monthsMean ~27.5 months
Primary outcomeMajor adverse cardiac eventsAll-cause mortality, MI, stroke
ResultDid not demonstrate excess MACE vs placebo in the primary analysis.Associated with higher composite event rates in this cohort.
Evidence strengthHighModerate
Major limitationSelected high-risk population; monitoring protocols differ in practice.Confounding, treatment selection, and later dataset concerns.

Built for clinicians who do not have hours to spare

From $129/month. Cancel anytime.

View pricing